These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 11029467)

  • 1. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1.
    Delgado M; Ganea D
    J Biol Chem; 2001 Jan; 276(1):369-80. PubMed ID: 11029467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M; Ganea D
    J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.
    Delgado M; Munoz-Elias EJ; Kan Y; Gozes I; Fridkin M; Brenneman DE; Gomariz RP; Ganea D
    J Biol Chem; 1998 Nov; 273(47):31427-36. PubMed ID: 9813054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia.
    Delgado M
    Biochem Biophys Res Commun; 2002 Oct; 297(5):1181-5. PubMed ID: 12372411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
    Delgado M; Ganea D
    J Neuroimmunol; 2000 Oct; 110(1-2):97-105. PubMed ID: 11024538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
    Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M
    Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
    Delgado M; Ganea D
    J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M; Ganea D
    J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
    Delgado M; Jonakait GM; Ganea D
    Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
    Delgado M; Leceta J; Ganea D
    J Leukoc Biol; 2003 Jan; 73(1):155-64. PubMed ID: 12525573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation.
    Delgado M; Ganea D
    J Biol Chem; 1999 Nov; 274(45):31930-40. PubMed ID: 10542221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
    Kim WK; Kan Y; Ganea D; Hart RP; Gozes I; Jonakait GM
    J Neurosci; 2000 May; 20(10):3622-30. PubMed ID: 10804204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.
    Delgado M
    Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide.
    Delgado M; Leceta J; Abad C; Martinez C; Ganea D; Gomariz RP
    J Neuroimmunol; 1999 Sep; 99(1):61-71. PubMed ID: 10496178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
    Drahushuk K; Connell TD; Higgins D
    J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).
    Taupenot L; Mahata SK; Wu H; O'Connor DT
    J Clin Invest; 1998 Feb; 101(4):863-76. PubMed ID: 9466982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.